Biolegend, 628506, Alexa Fluor® 647 anti-Cytokeratin 19 Antibody
100microg
Catalog Number: 628506
Send an RFQ.
Category
Loading…
| Verified Reactivity | Human |
|---|---|
| Antibody Type | Monoclonal |
| Host Species | Mouse |
| Immunogen | Human mammary carcinoma cell line MCF-7 |
| Formulation | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide. |
| Preparation | The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 647 under optimal conditions. |
| Concentration | 0.5 mg/ml |
| Storage & Handling | The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze. |
| Application | ICC - Quality tested |
| Recommended Usage | Each lot of this antibody is quality control tested by immunocytochemistry. For immunocytochemistry, a concentration range of 1.0 - 5.0 μg/ml is recommended. It is recommended that the reagent be titrated for optimal performance for each application. * Alexa Fluor® 647 has a maximum emission of 668 nm when it is excited at 633 nm / 635 nm. Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.View full statement regarding label licenses |
| Excitation Laser | Red Laser (633 nm) |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Application Notes |
|---|
| Additional reported applications (for the relevant formats) include: immunoprecipitation, immunohistochemistry of paraffin-embedded sections, immunocytochemistry, and ELISA. |
| Application References(PubMed link indicates BioLegend citation) | Karsten U, et al. 1985. Eur. J. Cancer Clin. Oncol. 21:733. Nishikata T,et al. Anticancer Res. 33:2867. PubMed |
|---|
| Product Citations | Seaman S, et al. 2017. Cancer Cell. 31:501. PubMed Pham K, et al. 2016. Am J Pathol. 186: 1537-1546. PubMed Lai BFL, et al. 2021. Nature Protocols. 16(4):2158-2189. PubMed |
|---|
| RRID | AB_2563651 (BioLegend Cat. No. 628506) |
|---|
| Structure | Type I intermediate filament protein, contains three coiled-coil domains, lacks C-terminal non-helical extension found in other keratins, approximately 40-44 kD. Cytokeratin 19 is a heterotetramer composed of two type I and two type II keratin subunits. |
|---|
| Distribution | Expressed in the periderm (transient superficial layer enveloping developing epidermis), also expressed in muscle, intestine, bile duct, esophagus, stomach, and thymus. Upregulated by vitamin A. |
|---|
| Function | Intermediate filament protein involved with the cytoskeleton. May play a critical role in embryogenesis |
|---|
| Interaction | Interacts with pinin |
|---|
| Modification | Phosphorylation (Ser10, Ser35) |
|---|
| Biology Area | Cell Biology, Cell Motility/Cytoskeleton/Structure, Neuroscience, Neuroscience Cell Markers |
|---|
| Molecular Family | Intermediate Filaments |
|---|
| Antigen References | 1. Bader BL, et al. 1986. EMBO J. 5:1865. 2. Eckert RL. 1988. Proc. Natl. Acad. Sci. 85:1114. 3. Stasiak PC and Lane EB. 1987 Nucleic Acids Res. 15:10058. |
|---|
| Gene ID | 3880 |
|---|
| UniProt | View information about Cytokeratin 19 on UniProt.org |
|---|
| Clone | A53-B/A2 |
|---|
| Regulatory Status | RUO |
|---|
| Other Names | Keratin 19, Keratin 19 type 1 cytoskeletal |
|---|
| Isotype | Mouse IgG2a, κ |
|---|
